Korea May Adopt Further Cost-Containment Steps Under 'Moon Jae-In Care' – IQVIA
Executive Summary
Korea is expected to feel the pressure to introduce more drug cost-containment measures amid rapidly rising National Health Insurance expenditures, IQVIA predicts. In particular, expenses associated with implementation of 'Moon Jae-in Care' could erode NHI financial surpluses in the short-medium term.
You may also be interested in...
Korea To Reform Reimbursement Management To Cut Expenditure
To trim the healthcare financial burden and boost the country’s national health insurance coverage as planned, South Korea will introduce a drug re-evaluation system to adjust prices of both novel and generic drugs, drawing a negative response from the pharma industry.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.